• Explore /
  • Poster
  • / Tracking plasticity along with proliferation and immune evasion using FOXC1, MKI67 and PDL1 for prediction of therapeutic response and risk for hyperprogressive disease with PD1/PDL1 inhibitors in advanced/metastatic cancers: Pan-tumor validation in clinical trial and real-world cohorts.

Tracking plasticity along with proliferation and immune evasion using FOXC1, MKI67 and PDL1 for prediction of therapeutic response and risk for hyperprogressive disease with PD1/PDL1 inhibitors in advanced/metastatic cancers: Pan-tumor validation in clinical trial and real-world cohorts.

Abstract Poster

Authors

null

Partha S Ray

Onconostic Technologies, Evanston, IL

Partha S Ray , Tania Ray , Clive R Taylor , Robert Hussa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Tissue-Based Biomarkers

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2627)

DOI

10.1200/JCO.2023.41.16_suppl.2627

Abstract #

2627

Poster Bd #

469

Abstract Disclosures

Similar Posters

First Author: Eric Nadler

First Author: Melissa Lynne Johnson

First Author: Roy S. Herbst

First Author: Panpan Zhang